Structure Therapeutics (NASDAQ:GPCR) Trading Up 4.7% - Time to Buy?

Shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report) traded up 4.7% during trading on Monday . The stock traded as high as $22.35 and last traded at $22.74. 203,750 shares were traded during mid-day trading, a decline of 76% from the average session volume of 848,640 shares. The stock had previously closed at $21.73.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GPCR. William Blair assumed coverage on Structure Therapeutics in a report on Friday, February 28th. They issued an "outperform" rating on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $89.00 price target on shares of Structure Therapeutics in a research note on Monday. Citigroup initiated coverage on Structure Therapeutics in a report on Friday, May 2nd. They issued a "buy" rating and a $60.00 target price for the company. HC Wainwright cut their price target on shares of Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a report on Monday, May 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $65.00 target price on shares of Structure Therapeutics in a report on Monday. Seven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $76.17.

Structure Therapeutics Price Performance

The stock has a fifty day moving average of $23.32 and a 200 day moving average of $24.06. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -25.72 and a beta of -1.87.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). As a group, equities analysts expect that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the stock. Zimmer Partners LP boosted its position in Structure Therapeutics by 77.1% during the first quarter. Zimmer Partners LP now owns 100,776 shares of the company's stock worth $1,744,000 after purchasing an additional 43,876 shares in the last quarter. Vestal Point Capital LP lifted its position in shares of Structure Therapeutics by 3.7% during the 1st quarter. Vestal Point Capital LP now owns 1,788,990 shares of the company's stock valued at $30,967,000 after buying an additional 63,990 shares in the last quarter. Cubist Systematic Strategies LLC increased its holdings in Structure Therapeutics by 3,326.0% in the 1st quarter. Cubist Systematic Strategies LLC now owns 54,816 shares of the company's stock worth $949,000 after acquiring an additional 53,216 shares in the last quarter. Point72 Europe London LLP lifted its holdings in Structure Therapeutics by 188.7% during the first quarter. Point72 Europe London LLP now owns 90,697 shares of the company's stock valued at $1,570,000 after purchasing an additional 59,277 shares in the last quarter. Finally, DAFNA Capital Management LLC grew its position in shares of Structure Therapeutics by 66.2% in the first quarter. DAFNA Capital Management LLC now owns 59,000 shares of the company's stock valued at $1,021,000 after purchasing an additional 23,500 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.